New cancer drug trial halted early – what we know

NCT ID NCT05194072

Terminated Disease control Sponsor: Seagen, a wholly owned subsidiary of Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma cholangiocarcinoma endometrial carcinoma endometrium neoplasm fallopian tube cancer fallopian tube neoplasm gallbladder carcinoma gallbladder neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer non-small cell lung carcinoma ovarian cancer ovarian neoplasm ovarian serous adenocarcinoma peritoneal neoplasm primary peritoneal carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA CARCINOMA, NON-SMALL-CELL LUNG CHOLANGIOCARCINOMA ENDOMETRIAL NEOPLASMS FALLOPIAN TUBE NEOPLASMS GALLBLADDER CARCINOMA HER2 NEGATIVE BREAST NEOPLASMS HORMONE RECEPTOR POSITIVE BREAST NEOPLASMS OVARIAN NEOPLASMS PERITONEAL NEOPLASMS TRIPLE NEGATIVE BREAST NEOPLASMS

Contacts and locations

Locations

AdventHealth Celebration Infusion Center

Celebration, Florida, 34747, United States
AdventHealth Medical Group Oncology Research at Celebration

Celebration, Florida, 34747, United States
Community Health Network, Inc.

Indianapolis, Indiana, 46227, United States
Community Health Network, Inc.

Indianapolis, Indiana, 46250, United States
Community Health Network, Inc.

Indianapolis, Indiana, 46256, United States
Florida Cancer Specialists

Orlando, Florida, 32827, United States
Hamato-Onkologische Phase 1 Unit der Charite/Charite Research Organisation

Berlin, 12200, Germany
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Northwestern Medical Group

Chicago, Illinois, 60611, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
Presbyterian/St Lukes Medical Center

Denver, Colorado, 80218, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
START Madrid-Hospital Universitario HM Sanchinarro

Madrid, 28050, Spain
START Midwest

Grand Rapids, Michigan, 49546, United States
START Mountain Region

West Valley City, Utah, 84119, United States
Sarah Cannon Research Institute

London, W1G 6AD, United Kingdom
Sarah Cannon Research Institute - Pharmacy

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at Florida Cancer Specialists

Orlando, Florida, 32827, United States
South Texas Accelerated Research Therapeutics, LLC

San Antonio, Texas, 78229, United States
The Ottawa Hospital Cancer Centre

Ottawa, Ontario, K1H 8L6, Canada
The University of Texas M.D. Anderson Cancer Center

Houston, Texas, 77030, United States
The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services

Houston, Texas, 77030, United States
UCHealth Sue Anschutz-Rodgers Eye Center

Aurora, Colorado, 80045, United States
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)

Aurora, Colorado, 80045, United States
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)

Aurora, Colorado, 80045, United States
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.